產(chǎn)品詳情
簡單介紹：
重組人可溶性Fas受體/ TNFRSF6蛋白與其它公司提供的重組蛋白不同，rHusFasR/TNFRSF6蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨(dú)有的全自動蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人可溶性Fas受體/ TNFRSF6蛋白（全長序列）產(chǎn)品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組人可溶性Fas受體/ TNFRSF6蛋白
| Synonyms | TNFRSF6, CD95, Apo I, Fas Antigen |
| Species | Human |
| Accession | P25445 |
| GeneID | 355 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人可溶性Fas受體/ TNFRSF6蛋白Approximately 17.6 kDa, a single non-glycosylated polypeptide chain containing 157 amino acids. |
| Quantity | 5μg/20μg/1000μg |
| AA Sequence | RLSSKSVNAQ VTDINSKGLE LRKTVTTVET QNLEGLHHDG QFCHKPCPPG ERKARDCTVN GDEPDCVPCQ EGKEYTDKAH FSSKCRRCRL CDEGHGLEVE INCTRTQNTK CRCKPNFFCN STVCEHCDPC TKCEHGIIKE CTLTSNTKCK EEGSRSN |
| Purity | > 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人可溶性Fas受體/ TNFRSF6蛋白Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the cytotoxicity of Jurkat cells is between 10-15 μg/ml in the presence of 2 ng/ml of rHuFas Ligand. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHusFasR/TNFRSF6 as determined by LAL method. |
| Reconstitution | 重組人可溶性Fas受體/ TNFRSF6蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人可溶性Fas受體/ TNFRSF6蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Zhang W, Ramdas L, Shen W, et al. 2003. Cancer Biol Ther, 2: 572-8. 2. Takubo T, Kumura T, Nishiki S, et al. 2000. Acta Haematol, 103: 165-7. 3. Lautrette C, Loum-Ribot E, Petit D, et al. 2006. Apoptosis, 11: 1195-204. 4. Kovacic N, Grcevic D, Katavic V, et al. 2010. Lab Invest, 90: 402-13. 5. Kaufmann T, Strasser A, Jost PJ. 2012. Cell Death Differ, 19: 42-50. |
| Background | Fas and Fas Ligand (FasL) belong to the TNF superfamily and are type I and type II transmembrane proteins, respectively. Binding of FasL to Fas triggers apoptosis in Fas-bearing cells. The mechanism of apoptosis involves recruitment of pro-caspase 8 through an adaptor molecule called FADD followed by processing of the pro-enzyme to active forms. These active caspases then cleave various cellular substrates leading to the eventual cell death. sFasR is capable of inhibiting FasL-induced apoptosis by acting as a decoy receptor that serves as a sink for FasL. |
